

A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke

Reflecting
real-world
practice

CREGS investigates the routine clinical use of Cerebrolysin to compare its effectiveness to patients treated with standard therapy alone

Multinational


- Diverse population
- 1.865 patients
- From 16 different countries
- Across 4 continents – Europe, Asia, Africa, Latin America



Methodology

Highly specific research question	▶ Relevant, patient-centered
Strict methodology	▶ Pre-defined statistical analysis plan
Balanced comparisons	▶ Stratification
Generalizable results	▶ Applicable to diverse patient populations and practice
Follows published US framework for effectiveness trials	▶ GRACE (Good ReseArch for Comparative Effectiveness)

CREGS Like-to-Like Comparison
Multilevel Case-mix Standardization



Real-world data

- Evaluate interventions in **diverse** routine-care patient **populations**
- Reflect **clinical** scenarios differing within and between countries
- Treatment according to **local daily practice** and local SmPCs
- **Adjunct** vs. standard therapy alone
- **Prospective** data collection
- Only essential inclusion criteria

Outcome measures

Primary outcome
mRS after 3 months

Secondary outcomes

- NIHSS at day 21 + after 3 months
- mRS at day 21
- MoCA after 3 months
- Patients with excellent recovery (mRS score 0-1) after 3 months
- Patients with functional independence (mRS score 0-2) after 3 months

Safety analysis